Taking on analysts’ expectations and winning: Aethlon Medical Inc. (AEMD)

Aethlon Medical Inc. (NASDAQ: AEMD) stock fell -13.77% on Friday to $1.44 against a previous-day closing price of $1.67. With 4.64 million shares changed hands, the volume of the stock remained heavier than its average volume of 4.07 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $1.6300 whereas the lowest price it dropped to was $1.4100. The 52-week range on AEMD shows that it touched its highest point at $5.99 and its lowest point at $0.88 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 0.73.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AEMD was up-trending over the past week, with a rise of 4.35%, but this was up by 39.81% over a month. Three-month performance surged to 35.21% while six-month performance rose 1.41%. The stock lost -72.36% in the past year, while it has lost -22.58% so far this year. A look at the trailing 12-month EPS for AEMD yields -0.70 with Next year EPS estimates of -0.86. For the next quarter, that number is -0.22. This implies an EPS growth rate of -8.20% for this year and 2.30% for next year.

Float and Shares Shorts:

At present, 16.64 million AEMD shares are outstanding with a float of 15.67 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.61 million, which was 3.87% higher than short shares on Jun 14, 2022. In addition to Dr. Charles J. Fisher Jr., M.D. as the firm’s CEO, Director & Member of Extracorporeal Therapy Advisory Board, Mr. Steven P. Larosa M.D. serves as its Chief Medical Officer & Acting Chief Scientific Officer.

Institutional Ownership:

Through their ownership of 7.72% of AEMD’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 4.32% of AEMD, in contrast to 4.08% held by mutual funds. Shares owned by individuals account for 0.87%. As the largest shareholder in AEMD with 3.16% of the stake, The Vanguard Group, Inc. holds 487,112 shares worth 487,112. A second-largest stockholder of AEMD, Renaissance Technologies LLC, holds 270,297 shares, controlling over 1.75% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in AEMD, holding 164,952 shares or 1.07% stake. With a 1.90% stake in AEMD, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 292,852 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.15% of AEMD stock, is the second-largest Mutual Fund holder. It holds 176,989 shares valued at 0.2 million. Fidelity Extended Market Index Fu holds 0.59% of the stake in AEMD, owning 90,173 shares worth 0.1 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AEMD since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AEMD analysts setting a high price target of $4.00 and a low target of $4.00, the average target price over the next 12 months is $4.00. Based on these targets, AEMD could surge 177.78% to reach the target high and rise by 177.78% to reach the target low. Reaching the average price target will result in a growth of 177.78% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AEMD will report FY 2023 earnings on 06/28/2023. Analysts have provided yearly estimates in a range of -$0.85 being high and -$0.91 being low. For AEMD, this leads to a yearly average estimate of -$0.88. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Aethlon Medical Inc. surprised analysts by -$0.12 when it reported -$0.26 EPS against a consensus estimate of -$0.14. The surprise factor in the prior quarter was -$0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.20 and the low estimate is -$0.24. The average estimate for the next quarter is thus -$0.22.

Summary of Insider Activity:

Insiders traded AEMD stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 8 over the past year. The total number of shares bought during that period was 0 while 19,440 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *